Top Mental Health Stocks
Discover investment opportunities in Top Mental Health Stocks using our Smart AI Filter.
AI is processing your request...
AI is analyzing your request
Scanning thousands of stocks to find the best matches...
Discover investment opportunities in Top Mental Health Stocks using our Smart AI Filter.
AI is processing your request...
Scanning thousands of stocks to find the best matches...
Discover investment opportunities in Top Mental Health Stocks using our Smart AI Filter.
AI is processing your request...
Scanning thousands of stocks to find the best matches...
Discover investment opportunities in Top Mental Health Stocks using our Smart AI Filter.
8 stocks found for "Top Mental Health Stocks"
Security name | Expected returns | Sharpe Ratio | Beta | Volatility | P/E Ratio | Dividend Yield |
---|---|---|---|---|---|---|
0.60 | ±27.2% | 15.6 | 3.47% | |||
1.91 | ±77.6% | -1.5 | 3.19% | |||
1.28 | ±88.5% | -5.2 | 0.00% | |||
0.59 | ±31.6% | 34.5 | 0.77% | |||
0.32 | ±24.8% | 8.7 | 6.75% | |||
1.50 | ±63.5% | -2.3 | 0.00% | |||
1.03 | ±49.2% | 6.1 | 2.00% | |||
0.37 | ±19.7% | 14.7 | 3.18% |
This search uses our Smart AI Filter to identify stocks matching your criteria. Results are ranked by relevance and include key financial metrics to help you make informed investment decisions.
Get personalized stock recommendations, save custom screens, and access premium filters. All our screening tools are free—signing up gives you more personalized results and the ability to save your research.
Compliance disclosure:
The securities listed on this website have not paid to be included in the results. The inclusion of any securities in the results shown does not imply any relationship with PortfolioPilot. The order of the results is ranked based on the Sharpe Ratio, which is a measure of risk-adjusted return. Please note that these listings are not recommendations or financial advice. Past performance is not indicative of future results.
Q: What makes TDOC a compelling choice for telehealth investments?
A: TDOC, or Teladoc Health, is a leader in the telehealth industry, providing virtual care services. Its robust platform and extensive network position it well to benefit from the growing demand for remote healthcare solutions, particularly amplified during the COVID-19 pandemic.
Q: How does CVS integrate mental health services into its offerings?
A: CVS offers mental health services through MinuteClinic locations and its HealthHUBs, which are designed to provide comprehensive health and wellness support, including access to mental health professionals, thus broadening its healthcare services scope beyond traditional pharmacy operations.
Q: Why might investors consider HIMS for mental health solutions?
A: HIMS offers online health and wellness services, including mental health treatments like anxiety and depression therapy. Its direct-to-consumer model capitalizes on the convenience and accessibility of telehealth, appealing to tech-savvy patients seeking remote mental health solutions.
Q: What role does LYRA play in digital health and mental wellness?
A: LYRA Health specializes in mental wellness by connecting employees to mental health professionals through its digital platform. Companies value its easy access to reliable care, which supports workforce mental health, an increasing priority in corporate wellness.
Q: Are there risks associated with investing in ONEM within the mental health sector?
A: ONEM, or One Medical, provides primary care services with mental health integrated within its offerings. Regulatory challenges and reimbursement pressures could impact its financial performance, necessitating thorough examination of its strategic and policy navigation capabilities.
Q: How does PEAR innovate within the mental health tech sector?
A: PEAR Therapeutics develops prescription digital therapeutics (PDTs) offering evidence-based interventions for mental health conditions like depression. As a pioneer in this evolving field, PEAR's sustained innovation and market adoption remain critical for potential growth.
President Donald Trump demanded several pharmaceutical companies cut down their drug prices for American consumers Thursday, issuing a Sept. 29 deadline for the businesses to 'end the free ride of American innovation by European and other developed nations."
Read more